|Articles|January 1, 2006

Pharmacy Times

  • Volume 0
  • 0

Hydase (hyaluronidase injection, USP)

PrimaPharm Inc (San Diego, Calif) recently received FDA approval for a new drug application for Hydase 150 units/mL for use as a spreading agent to facilitate the dispersion and absorption of other drugs. Hydase is also indicated for hypodermoclysis and as an adjunct in the subcutaneous urography for improving resorption of radiopaque agents. The product is supplied sterile as 150 USP units of hyaluronidase per mL in a 2-mL nonpreserved, single-use glass vial. For more information, call 866-339-6589, or visit www.primapharm.net.

Articles in this issue

almost 20 years ago

High Alert Insulin Bin

almost 20 years ago

Humira (adalimumab)

almost 20 years ago

INVANZ (ertapenem for injection)

almost 20 years ago

Compounding HOTLINE

almost 20 years ago

Can You Read These Rxs?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME